- Companies
- Zephyr AI
Zephyr AI Funding, Investors & Competitors
Zephyr AI has raised $130M across 2 funding rounds, most recently a $111M Series A in March 2024.
Last Zephyr AI funding round
$111M
Series A · Mar 2024
Cumulative funding Zephyr AI raised
$130M
across 2 funding rounds
Key investors in Zephyr AI
Liquid 2 Ventures
BoxGroup
AME Cloud Ventures
Revolution Growth
EPIQ Capital Group
Eli Lilly & Company Foundation
Lerner Enterprises
MedStar Health
About Zephyr AI
Zephyr AI is an Austin-headquartered healthcare AI company accelerating drug discovery and precision medicine. The platform analyzes multimodal patient data from electronic health records and genomics to identify novel targets and biomarkers. Zephyr AI partners with biopharma firms like Pfizer and health systems such as Mayo Clinic to validate therapies in oncology and cardiology. Its knowledge graph integrates real-world evidence for clinical trial optimization and personalized treatment recommendations.
Founded
2020
HQ
Website
Status
Privately held
Customer focus
B2B
Revenue model
Subscription
Zephyr AI Funding History
Zephyr AI has raised a total of $130M across 2 funding rounds.
Zephyr AI's first fundraising round was a $19M seed round in March 2022. The most recent completed round was a $111M Series A in March 2024.
Zephyr AI funding rounds
| Date | Stage | Investors | Raised | Deal Summary |
|---|---|---|---|---|
| Mar 2024 | Series A | Eli Lilly & Company Foundation (lead); EPIQ Capital Group (lead); Jeff Skoll (lead); Revolution Growth (lead) | $111M | Zephyr AI, a McLean, Virginia-based healthcare technology company founded in 2020 or 2021, develops fast and explainable AI solutions to democratize precision medicine, focusing on oncology and cardiometabolic diseases. The company curates comprehensive healthcare datasets through partnerships and proprietary sources, merging them with machine learning algorithms to generate insights for drug development, clinical trials, clinical decision support, patient stratification, and response predictions. It emphasizes data federation tools to handle real-world patient data and representation learning for biological context in predictions. On March 13, 2024, Zephyr AI closed a $111 million Series A funding round with participation from Revolution Growth, Eli Lilly & Company, Jeff Skoll, EPIQ Capital Group, and about 30 other investors. The round, which began in October 2023, followed a $18.5 million seed round in March 2022 led by Red Cell Partners. Proceeds will enhance analytical speed, expand training and validation datasets, and grow scientific and commercial teams to accelerate delivery of its pipeline of insights. Zephyr AI had two abstracts accepted at the American Association for Cancer Research (AACR) annual meeting in San Diego, April 5-10, 2024, showcasing emerging scientific insights. Leaders like Co-Founder/Interim CEO/CTO Jeff Sherman and Executive Chairman Grant Verstandig highlighted the funding's role in transforming precision medicine and clinical trial outcomes. The investment aligns with surging interest in AI-driven deep tech for healthcare, where Zephyr AI positions itself at the forefront by addressing challenges in real-world data navigation and providing translatable insights for approved medicines and drugs in development. |
| Mar 2022 | Seed | Lerner Enterprises (lead); M-Cor Holdings (lead); MedStar Health; Liquid 2 Ventures; BoxGroup; Allen Chao; AME Cloud Ventures | $19M | Zephyr AI is a healthcare technology company founded in 2020 and based in the McLean/Tysons Corner/Fairfax Station area of Virginia, specializing in AI-driven precision medicine, drug discovery, drug rescue, and clinical decision support using large complex data and proprietary algorithms. The company partners with health systems, insurance plans, and biotech firms to improve outcomes, costs, and quality in areas like oncology, clinicogenomics, real-world evidence, and predictive biomarkers. It develops interpretable AI solutions for patient stratification, drug sensitivity prediction, clinical trial optimization, and multimodal data analysis in biotechnology and pharmaceuticals. On March 30, 2022, Zephyr AI completed a Seed VC funding round with lead investors Lerner Enterprises and M-Cor Holdings, alongside participants including Allen Chao, AME Cloud Ventures, BoxGroup, Liquid 2 Ventures, and MedStar Health, matching the query details. This was the company's first funding round, preceding later raises. Zephyr AI's next major round was a $111 million Series A on March 13, 2024, led by or involving Revolution Growth, EPIQ Capital Group, Eli Lilly and Company Foundation, Jeff Skoll, and Red Cell Partners, bringing total funding to approximately $129.5M to $148M across 2-3 rounds. The company has grown to 31-74 employees, focusing on AI in healthcare analytics, biomarker discovery, and real-world data cohorts for NSCLC, cardiometabolic outcomes, and immune therapies. |
Who has invested in Zephyr AI?
11 investors have backed Zephyr AI across its funding rounds, including Liquid 2 Ventures, BoxGroup, AME Cloud Ventures, Revolution Growth, EPIQ Capital Group and Eli Lilly & Company Foundation.
Lead investors include Eli Lilly & Company Foundation, EPIQ Capital Group, Jeff Skoll, Revolution Growth, Lerner Enterprises and 1 other investor.
Zephyr AI Investors
| Investor | HQ | Rounds | Role | First check |
|---|---|---|---|---|
| 1 | Participant | Mar 2022 | ||
| 1 | Lead | Mar 2024 | ||
| -- | 1 | Lead | Mar 2022 | |
| 1 | Participant | Mar 2022 | ||
| 1 | Participant | Mar 2022 | ||
| 1 | Lead | Mar 2022 | ||
| 1 | Participant | Mar 2022 | ||
| 1 | Lead | Mar 2024 | ||
| 1 | Lead | Mar 2024 | ||
This data is available for Pro users. Sign up to see all 11 Zephyr AI investors. Start Free Trial | ||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAcquisitions by Zephyr AI
Zephyr AI has acquired 1 company to date.
Last acquisition by Zephyr AI was on August 26th 2025. Zephyr AI acquired Aster Insights for undisclosed valuation.
Latest Acquisitions by Zephyr AI
| Description | Aster Insights is a Boston-based oncology bioinformatics company that delivers clinical decision support tools integrating genomic sequencing data with patient electronic health records. Its platform analyzes tumor molecular profiles to recommend precision therapies, serving oncologists at major cancer centers including MD Anderson and Memorial Sloan Kettering. Founded in 2019, the firm processes data from over 50,000 patient cases to generate actionable insights on drug response predictions and biomarker discovery. |
| HQ Country | |
| HQ City | - |
| Deal Date | 26 Aug 2025 |
| Valuation | undisclosed |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Zephyr AI acquisitions and their M&A valuation multiples. Start Free Trial | |
Zephyr AI Competitors
Zephyr AI competitors include listed companies like IQVIA, IDEXX Laboratories, GE HealthCare and ICON plc, and private ones like Uptake Technologies and Commure.
| Company | HQ | Status | Revenue | EBITDA | Valuation | Revenue Multiple |
|---|---|---|---|---|---|---|
| Private | $100M | - | $2.3B | 23.0x | ||
| Publicly listed | $16B | $3.4B | $44B | 3.4x | ||
| Publicly listed | $4.3B | $1.5B | $40B | 8.9x | ||
| Publicly listed | $21B | $3.7B | $29B | 1.8x | ||
| Publicly listed | $8.3B | $816M | $13B | 1.9x | ||
| Private | $200M | - | $7B | 35.0x |
Zephyr AI Public Comps
Zephyr AI is still privately-owned, but its public comps include Eli Lilly, Johnson & Johnson, AbbVie, Palantir, Merck, Roche, Novartis, AstraZeneca, Amgen and Novo Nordisk.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $65B | $28B | 16.5x | 13.1x | 38.7x | 27.0x | |||
| $94B | $40B | 7.2x | 6.8x | 17.0x | 18.3x | |||
| $61B | $17B | 8.7x | 8.1x | 30.6x | 17.6x | |||
| $4.5B | $1.5B | 92.6x | 58.1x | 285.0x | 97.4x | |||
| $65B | $28B | 6.3x | 6.2x | 14.7x | 21.0x | |||
| $77B | $26B | 5.0x | 4.9x | 14.6x | 12.4x | |||
| $57B | $22B | 5.5x | 5.5x | 14.2x | 13.3x | |||
| $59B | $19B | 4.8x | 4.5x | 14.6x | 12.7x | |||
This data is available for Pro users. Sign up to see all Zephyr AI competitors and their valuation data. Start Free Trial | ||||||||
Common questions about Zephyr AI
| When was Zephyr AI founded? | Zephyr AI was founded in 2020. |
| Where is Zephyr AI headquartered? | Zephyr AI is headquartered in Washington, VA, United States. |
| Is Zephyr AI publicly listed? | No, Zephyr AI is a private, VC-backed company. |
| How much funding has Zephyr AI raised? | Zephyr AI has raised $130M across 2 funding rounds. |
| What was Zephyr AI's last funding round? | Zephyr AI's last funding round was a $111M Series A in March 2024, led by Eli Lilly & Company Foundation, EPIQ Capital Group, Jeff Skoll and Revolution Growth. |
| Who are Zephyr AI's investors? | Zephyr AI's investors include MedStar Health, Revolution Growth, M-Cor Holdings, Liquid 2 Ventures, BoxGroup, Lerner Enterprises, Allen Chao, EPIQ Capital Group, Eli Lilly & Company Foundation, Jeff Skoll and 1 other. |
| Which companies are comparable to Zephyr AI? | Companies comparable to Zephyr AI include Uptake Technologies, IQVIA, IDEXX Laboratories, GE HealthCare, ICON plc and Commure. |
| How many companies has Zephyr AI acquired? | Zephyr AI has acquired 1 company, including Aster Insights. |
See companies similar to Zephyr AI
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




